Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which in turn increases insulin release and decreases glucagon secretion in a glucose-dependent manner. ## Primary Indications Adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing The recommended dose is 5 mg orally once daily. ## Pediatric Dosing Dosing has not been established in pediatric patients. ## Dose Adjustments No dose adjustment is required for patients with renal or hepatic impairment. ## Contraindications * Known hypersensitivity to linagliptin or any excipients. * History of serious hypersensitivity reactions to DPP-4 inhibitors. ## Adverse Effects The most common adverse effects include nasopharyngitis, diarrhea, and upper respiratory tract infection. More serious adverse effects include: * Hypoglycemia (especially when used in combination with sulfonylureas or insulin) * Hypersensitivity reactions * Pancreatitis * Joint pain (arthralgia) ## Key Drug Interactions * **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** May decrease linagliptin exposure and efficacy. Coadministration is not recommended. * **Sulfonylureas and Insulin:** Increased risk of hypoglycemia. Consider a lower dose of the sulfonylurea or insulin. ## Monitoring * Blood glucose levels to assess efficacy and guide dosing adjustments of other antidiabetic agents. * Monitor for signs and symptoms of pancreatitis (persistent severe abdominal pain, with or without vomiting). * Monitor for signs and symptoms of hypersensitivity reactions. ## Clinical Pearls * Linagliptin does not require dose adjustment in renal or hepatic impairment, making it a convenient option for patients with these comorbidities. * It can be taken with or without food. * Due to the risk of severe and persistent arthralgia, consider discontinuing if severe joint pain develops. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines before making clinical decisions.*